A great progress in the treatment of neovascular glaucoma
10.3980/j.issn.1672-5123.2020.6.13
- VernacularTitle:新生血管性青光眼治疗进展
- Author:
Qin-Yun Xia
1
Author Information
1. The Eye Center, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China
- Publication Type:Journal Article
- Keywords:
neovascular glaucoma;
panretinal photocoagulation;
anti-vascular endothelial growth factor;
combination therapy
- From:
International Eye Science
2020;20(6):987-989
- CountryChina
- Language:Chinese
-
Abstract:
Neovascular glaucoma(NVG)is a common refractory glaucoma in ophthalmology, which is usually secondary to central retinal vein occlusion(CRVO), diabetic retinopathy(DR), long-standing retinal detachment, ocular tumors, etc. Previous treatments mainly included panretinal photocoagulation(PRP), drugs, anti-glaucoma surgery or ciliary destruction, but the therapeutic effect was unsatisfactory. With the continuous development and application of anti-vascular endothelial growth factor(VEGF)drugs, combination therapy of anti-vascular endothelial growth factor(VEGF)drugs has been proposed gradually, and the success rate of NVG surgery has been increased significantly, and NVG can be controlled. The treatment progress of NVG in recent years will be described in detail.
- Full text:202006013.pdf
